Searched for
PERTUZUMAB
Biocon CEO forecasts H2 results to outperform H1; company posts 52% fall in Q2 net profit; revenue up 2%Biocon reported a 52% drop in second-quarter net profit due to shipment delays caused by geopolitical issues. The company expects revenue g...- Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...
- Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar PebrilzoBiocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, ...
- Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely sellerBiocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...
- Government panel plans to retain rule allowing doorstep drug deliveryA government sub-committee has decided to uphold the 2020 rule for doorstep delivery of medicines, recognizing its critical importance for ...
- Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block dealActive Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development...
- Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bidRating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's propos...
- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- BahiaFarma, Biocon, Bionovis inks MoU in pharma sectorIndia and Brazil signed multiple Memoranda of Understanding (MoUs) during Brazilian President Lula da Silva's visit. Key agreements include...
- Biocon Biologics to introduce three new biosimilars for cancer treatmentBiocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...
- Alkem launches breast cancer biosimilar in IndiaAlkem Laboratories has launched Pertuza, a biosimilar of pertuzumab, in India for treating HER2-positive breast cancer. This indigenously d...
- Crucial drugs to be more affordable after GST cutThe government has significantly reduced GST rates on 41 highly priced medicines, including those for cancer, rare diseases, and heart cond...
- Supreme Court asks Zydus Lifesciences to approach Delhi HC over ban on selling breast cancer drug SigrimaThe Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order that prevents t...
- Delhi HC allows Zydus Lifesciences to sell breast cancer drug SigrimaThe Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being si...
- Zydus barred from selling cancer biosimilar, for nowThe Delhi High Court has temporarily barred Zydus Lifesciences from selling its breast cancer drug Sigrima, a biosimilar of Roche's Perjeta...
- Stocks in news: JSW Infra, Stanley Lifestyles, SAMHI Hotels, Bank Of Baroda, IREDAIndicating that the company is still interested in the mega Tajpur deep sea port in West Bengal, JSW Infrastructure Ltd said that it remain...
- Roche launches antibody drug for breast cancer in IndiaThe drug is approved for treating both early and late stage or metastatic HER2-positive breast cancer.
- Roche Pharma launches drug to treat breast cancerPHESGO was first approved by the US FDA in June 2020 during the peak of the Covid pandemic, by the European Medicines Agency (EMA) in Decem...
Load More
